Results 131 to 140 of about 4,797,534 (248)
More about the basic assumptions of t-test: normality and sample size. [PDF]
Kim TK, Park JH.
europepmc +1 more source
ABSTRACT Background Sickle cell disease (SCD) has undergone major changes in the last decades. Its prevalence has been steadily increasing and numerous advances have been made in the management of the disease. However, the effect in real‐life setting of these major changes is unknown, particularly in a Canadian environment. Procedure We aimed to assess
Maude Cigna +16 more
wiley +1 more source
A Tutorial on Conducting and Interpreting a Bayesian Independent T-Test Using Open-Source Software. [PDF]
Malone HE, Coyne I.
europepmc +1 more source
Inhibition effect of miR-150 on the progression of oral squamous cell carcinoma by data analysis model based on independent sample T-test. [PDF]
Wu C, Yang M, Chen H.
europepmc +1 more source
ABSTRACT Background Person‐centred follow‐up care based on evidence‐based clinical practice guidelines and providing individualised information should help to inform and reassure survivors about their medical and psychosocial situation and provide treatment and support where needed.
Gisela Michel +36 more
wiley +1 more source
Constructing a T-Test for Value Function Comparison of Individualized Treatment Regimes in the Presence of Multiple Imputation for Missing Data. [PDF]
Lu M +8 more
europepmc +1 more source
Can the Immune System Perform a t-Test? [PDF]
Faria BF +2 more
europepmc +1 more source
ABSTRACT Background Secretory phospholipase A2 (sPLA2) is an inflammatory mediator linked to acute chest syndrome (ACS) in sickle cell disease (SCD), a serious complication that can develop during an acute vaso‐occlusive pain episode (VOE). Plasma sPLA2 levels have been proposed as a potential biomarker for predicting ACS onset.
Rawan Korman +10 more
wiley +1 more source
A simple guide to the use of Student's t-test, Mann-Whitney U test, Chi-squared test, and Kruskal-Wallis test in biostatistics. [PDF]
Chicco D, Sichenze A, Jurman G.
europepmc +1 more source
ABSTRACT Background Therapeutic apheresis (TA) is an established treatment modality for hematologic, neurologic, and immunologic disorders, yet access remains severely limited in sub‐Saharan Africa. Donor apheresis, including platelet apheresis collection from healthy donors, represents an important complementary modality supporting blood product ...
Nosa Bazuaye +33 more
wiley +1 more source

